| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brachytherapy | 75 | 2023 | 977 | 15.610 |
Why?
|
| Proton Therapy | 61 | 2024 | 1577 | 11.090 |
Why?
|
| Prostatic Neoplasms | 105 | 2023 | 5767 | 8.860 |
Why?
|
| Radiotherapy, Intensity-Modulated | 65 | 2024 | 2104 | 7.040 |
Why?
|
| Head and Neck Neoplasms | 73 | 2024 | 3976 | 6.820 |
Why?
|
| Oropharyngeal Neoplasms | 36 | 2022 | 1105 | 6.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 47 | 2024 | 2370 | 3.720 |
Why?
|
| Radiotherapy Dosage | 77 | 2024 | 3842 | 3.590 |
Why?
|
| Magnetic Resonance Imaging | 42 | 2023 | 7702 | 3.370 |
Why?
|
| Radiation Injuries | 24 | 2020 | 1411 | 3.290 |
Why?
|
| Prostate | 24 | 2023 | 1088 | 3.200 |
Why?
|
| Iodine Radioisotopes | 18 | 2023 | 371 | 3.120 |
Why?
|
| Eye Neoplasms | 8 | 2023 | 247 | 2.380 |
Why?
|
| Radiosurgery | 13 | 2023 | 1330 | 2.270 |
Why?
|
| Radiation Oncology | 10 | 2021 | 529 | 2.230 |
Why?
|
| Carcinoma, Adenoid Cystic | 9 | 2020 | 421 | 2.210 |
Why?
|
| Carcinoma, Squamous Cell | 37 | 2024 | 5437 | 2.180 |
Why?
|
| Xerostomia | 7 | 2021 | 190 | 2.180 |
Why?
|
| Radiotherapy, Image-Guided | 14 | 2020 | 304 | 2.150 |
Why?
|
| Nasopharyngeal Neoplasms | 12 | 2023 | 323 | 2.110 |
Why?
|
| Alphapapillomavirus | 6 | 2022 | 171 | 1.980 |
Why?
|
| Palladium | 7 | 2023 | 56 | 1.960 |
Why?
|
| Quality Assurance, Health Care | 8 | 2020 | 585 | 1.900 |
Why?
|
| Nomograms | 7 | 2021 | 313 | 1.900 |
Why?
|
| Papillomavirus Infections | 12 | 2021 | 980 | 1.890 |
Why?
|
| Lacrimal Apparatus Diseases | 6 | 2020 | 137 | 1.860 |
Why?
|
| Radioisotopes | 7 | 2020 | 177 | 1.820 |
Why?
|
| Photons | 7 | 2020 | 507 | 1.800 |
Why?
|
| Male | 206 | 2023 | 123000 | 1.720 |
Why?
|
| Humans | 296 | 2024 | 261506 | 1.630 |
Why?
|
| Quality of Life | 24 | 2023 | 4532 | 1.580 |
Why?
|
| Lacrimal Apparatus | 5 | 2023 | 181 | 1.540 |
Why?
|
| Phantoms, Imaging | 12 | 2020 | 1271 | 1.540 |
Why?
|
| Radiometry | 18 | 2022 | 980 | 1.530 |
Why?
|
| Re-Irradiation | 8 | 2021 | 163 | 1.440 |
Why?
|
| Prostatectomy | 11 | 2023 | 962 | 1.440 |
Why?
|
| Patient Reported Outcome Measures | 11 | 2020 | 799 | 1.410 |
Why?
|
| Organs at Risk | 13 | 2023 | 514 | 1.390 |
Why?
|
| Neoplasm Recurrence, Local | 38 | 2023 | 10035 | 1.380 |
Why?
|
| Prostate-Specific Antigen | 21 | 2023 | 993 | 1.360 |
Why?
|
| Organ Sparing Treatments | 6 | 2019 | 277 | 1.260 |
Why?
|
| Papillomaviridae | 11 | 2022 | 624 | 1.250 |
Why?
|
| Carcinoma | 12 | 2023 | 2578 | 1.230 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 5 | 2020 | 96 | 1.220 |
Why?
|
| Radiation Dosage | 12 | 2022 | 1014 | 1.190 |
Why?
|
| Aged | 123 | 2023 | 70117 | 1.150 |
Why?
|
| Rectum | 7 | 2020 | 467 | 1.120 |
Why?
|
| Middle Aged | 127 | 2023 | 86204 | 1.110 |
Why?
|
| Fiducial Markers | 3 | 2016 | 96 | 1.100 |
Why?
|
| Health Care Costs | 7 | 2021 | 674 | 1.050 |
Why?
|
| Urination Disorders | 5 | 2018 | 61 | 1.040 |
Why?
|
| Prospective Studies | 39 | 2022 | 12873 | 1.020 |
Why?
|
| Image Processing, Computer-Assisted | 8 | 2020 | 1648 | 1.010 |
Why?
|
| Cost-Benefit Analysis | 4 | 2018 | 945 | 0.970 |
Why?
|
| Tomography, X-Ray Computed | 27 | 2023 | 7551 | 0.970 |
Why?
|
| Radiotherapy | 11 | 2018 | 1824 | 0.940 |
Why?
|
| Eyelid Neoplasms | 7 | 2015 | 191 | 0.940 |
Why?
|
| Seminal Vesicles | 5 | 2020 | 152 | 0.930 |
Why?
|
| Algorithms | 15 | 2021 | 3890 | 0.920 |
Why?
|
| Protons | 8 | 2023 | 473 | 0.920 |
Why?
|
| Deglutition Disorders | 6 | 2020 | 447 | 0.910 |
Why?
|
| Radiotherapy, Conformal | 10 | 2020 | 902 | 0.900 |
Why?
|
| Androgen Antagonists | 13 | 2023 | 411 | 0.890 |
Why?
|
| Follow-Up Studies | 37 | 2023 | 14889 | 0.870 |
Why?
|
| Acetylcysteine | 2 | 2014 | 143 | 0.860 |
Why?
|
| Adult | 89 | 2023 | 77950 | 0.850 |
Why?
|
| Pelvis | 2 | 2023 | 362 | 0.850 |
Why?
|
| Retrospective Studies | 75 | 2024 | 37905 | 0.850 |
Why?
|
| Treatment Outcome | 54 | 2023 | 32848 | 0.820 |
Why?
|
| Nose Neoplasms | 4 | 2023 | 229 | 0.820 |
Why?
|
| Simulation Training | 2 | 2020 | 149 | 0.800 |
Why?
|
| Aged, 80 and over | 62 | 2023 | 29902 | 0.790 |
Why?
|
| Erectile Dysfunction | 2 | 2014 | 212 | 0.780 |
Why?
|
| Relative Biological Effectiveness | 4 | 2021 | 219 | 0.770 |
Why?
|
| Adenocarcinoma | 13 | 2023 | 7789 | 0.760 |
Why?
|
| Laryngeal Neoplasms | 7 | 2021 | 518 | 0.750 |
Why?
|
| Penis | 2 | 2012 | 123 | 0.750 |
Why?
|
| Urethral Diseases | 1 | 2020 | 36 | 0.740 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2020 | 43 | 0.730 |
Why?
|
| Ophthalmologic Surgical Procedures | 3 | 2018 | 177 | 0.720 |
Why?
|
| Taste | 2 | 2022 | 50 | 0.720 |
Why?
|
| Research Design | 2 | 2018 | 1544 | 0.710 |
Why?
|
| Radiotherapy, Computer-Assisted | 3 | 2012 | 126 | 0.700 |
Why?
|
| Female | 105 | 2023 | 141928 | 0.690 |
Why?
|
| Chemoradiotherapy | 12 | 2021 | 1946 | 0.690 |
Why?
|
| Urinary Bladder | 7 | 2020 | 575 | 0.680 |
Why?
|
| Dysgeusia | 1 | 2018 | 7 | 0.680 |
Why?
|
| Ageusia | 1 | 2018 | 3 | 0.680 |
Why?
|
| Parotid Gland | 3 | 2019 | 112 | 0.680 |
Why?
|
| Urethra | 5 | 2020 | 144 | 0.670 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2021 | 363 | 0.670 |
Why?
|
| Rectal Diseases | 3 | 2018 | 55 | 0.650 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 251 | 0.650 |
Why?
|
| Indazoles | 1 | 2020 | 297 | 0.640 |
Why?
|
| Cesium Radioisotopes | 1 | 2017 | 39 | 0.630 |
Why?
|
| Contrast Media | 5 | 2020 | 1472 | 0.610 |
Why?
|
| Survival Rate | 31 | 2020 | 12221 | 0.600 |
Why?
|
| Physicians | 5 | 2020 | 882 | 0.600 |
Why?
|
| Disease-Free Survival | 25 | 2023 | 10001 | 0.580 |
Why?
|
| Vaginal Neoplasms | 3 | 2008 | 152 | 0.580 |
Why?
|
| Robotic Surgical Procedures | 2 | 2023 | 481 | 0.580 |
Why?
|
| Radiotherapy, Adjuvant | 14 | 2023 | 2231 | 0.580 |
Why?
|
| Cisplatin | 7 | 2023 | 2432 | 0.570 |
Why?
|
| Orbital Neoplasms | 2 | 2015 | 224 | 0.570 |
Why?
|
| Osteoradionecrosis | 1 | 2017 | 123 | 0.540 |
Why?
|
| Societies, Medical | 3 | 2020 | 1335 | 0.540 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 479 | 0.540 |
Why?
|
| Orbit | 2 | 2024 | 205 | 0.540 |
Why?
|
| Penile Erection | 2 | 2014 | 86 | 0.530 |
Why?
|
| Piperidines | 2 | 2020 | 1035 | 0.520 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2014 | 25 | 0.500 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2021 | 2594 | 0.500 |
Why?
|
| Patient Selection | 5 | 2019 | 2055 | 0.500 |
Why?
|
| Skull Base Neoplasms | 5 | 2020 | 314 | 0.500 |
Why?
|
| Carbolines | 1 | 2014 | 27 | 0.500 |
Why?
|
| Neoplasm Staging | 32 | 2021 | 13658 | 0.500 |
Why?
|
| Patient Preference | 1 | 2016 | 218 | 0.480 |
Why?
|
| Particle Accelerators | 1 | 2016 | 352 | 0.470 |
Why?
|
| Internship and Residency | 4 | 2020 | 1375 | 0.470 |
Why?
|
| Paranasal Sinus Neoplasms | 3 | 2023 | 285 | 0.460 |
Why?
|
| Time Factors | 19 | 2020 | 12926 | 0.460 |
Why?
|
| Cobalt | 2 | 2010 | 55 | 0.450 |
Why?
|
| Neoplasms, Unknown Primary | 2 | 2018 | 192 | 0.450 |
Why?
|
| Urination | 1 | 2013 | 36 | 0.450 |
Why?
|
| Insurance Coverage | 4 | 2020 | 256 | 0.440 |
Why?
|
| Uncertainty | 5 | 2023 | 320 | 0.440 |
Why?
|
| Tonsillar Neoplasms | 3 | 2022 | 80 | 0.430 |
Why?
|
| Combined Modality Therapy | 17 | 2020 | 8865 | 0.420 |
Why?
|
| Dose-Response Relationship, Radiation | 8 | 2016 | 726 | 0.420 |
Why?
|
| Health Status | 4 | 2014 | 590 | 0.420 |
Why?
|
| Cohort Studies | 18 | 2021 | 9244 | 0.410 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 3 | 2017 | 110 | 0.410 |
Why?
|
| Computers | 2 | 2021 | 141 | 0.410 |
Why?
|
| Observer Variation | 3 | 2021 | 671 | 0.400 |
Why?
|
| Radiation Tolerance | 4 | 2021 | 629 | 0.400 |
Why?
|
| Salvage Therapy | 8 | 2023 | 2054 | 0.390 |
Why?
|
| Survival Analysis | 18 | 2020 | 9180 | 0.380 |
Why?
|
| Hypesthesia | 1 | 2010 | 22 | 0.380 |
Why?
|
| Salivary Gland Neoplasms | 3 | 2021 | 489 | 0.380 |
Why?
|
| Monitoring, Intraoperative | 1 | 2012 | 264 | 0.380 |
Why?
|
| Surveys and Questionnaires | 11 | 2020 | 5687 | 0.370 |
Why?
|
| Urinary Catheterization | 1 | 2011 | 117 | 0.370 |
Why?
|
| Texas | 10 | 2018 | 6311 | 0.370 |
Why?
|
| Cell Line, Tumor | 9 | 2021 | 14551 | 0.360 |
Why?
|
| Esophagitis | 2 | 2022 | 202 | 0.360 |
Why?
|
| Prognosis | 23 | 2021 | 21713 | 0.360 |
Why?
|
| Prosthesis Implantation | 1 | 2012 | 263 | 0.350 |
Why?
|
| Skull Base | 6 | 2021 | 199 | 0.350 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 5395 | 0.340 |
Why?
|
| United States | 22 | 2021 | 15433 | 0.340 |
Why?
|
| Positron-Emission Tomography | 8 | 2022 | 2173 | 0.340 |
Why?
|
| Cancer Care Facilities | 6 | 2016 | 884 | 0.340 |
Why?
|
| Radiotherapy Setup Errors | 3 | 2020 | 80 | 0.330 |
Why?
|
| Lymphatic Metastasis | 14 | 2022 | 4844 | 0.330 |
Why?
|
| DNA Repair | 4 | 2021 | 1872 | 0.330 |
Why?
|
| Organ Size | 2 | 2020 | 690 | 0.320 |
Why?
|
| Adenoma, Pleomorphic | 2 | 2020 | 63 | 0.320 |
Why?
|
| Printing, Three-Dimensional | 2 | 2020 | 129 | 0.320 |
Why?
|
| Body Burden | 1 | 2008 | 65 | 0.320 |
Why?
|
| Mouth Neoplasms | 3 | 2017 | 713 | 0.310 |
Why?
|
| Stomatitis | 4 | 2018 | 183 | 0.300 |
Why?
|
| Artifacts | 3 | 2020 | 532 | 0.300 |
Why?
|
| Induction Chemotherapy | 4 | 2021 | 669 | 0.300 |
Why?
|
| Radiography | 5 | 2016 | 1904 | 0.300 |
Why?
|
| Clinical Competence | 3 | 2020 | 1270 | 0.300 |
Why?
|
| Diethylstilbestrol | 1 | 2007 | 109 | 0.290 |
Why?
|
| Tumor Burden | 7 | 2017 | 1987 | 0.290 |
Why?
|
| Young Adult | 22 | 2021 | 21445 | 0.290 |
Why?
|
| Visual Acuity | 4 | 2018 | 873 | 0.280 |
Why?
|
| Cone-Beam Computed Tomography | 4 | 2020 | 202 | 0.270 |
Why?
|
| Preoperative Care | 1 | 2012 | 1529 | 0.270 |
Why?
|
| Neoplasms | 6 | 2021 | 15193 | 0.270 |
Why?
|
| Workflow | 3 | 2021 | 275 | 0.260 |
Why?
|
| Blood Transfusion | 2 | 2021 | 583 | 0.260 |
Why?
|
| Probability | 4 | 2022 | 866 | 0.260 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2018 | 476 | 0.250 |
Why?
|
| Glottis | 2 | 2019 | 67 | 0.250 |
Why?
|
| Monte Carlo Method | 5 | 2021 | 671 | 0.250 |
Why?
|
| Neoplasm Invasiveness | 6 | 2018 | 3981 | 0.250 |
Why?
|
| Computer Simulation | 3 | 2020 | 1529 | 0.250 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 761 | 0.240 |
Why?
|
| Apoptosis | 5 | 2021 | 7591 | 0.240 |
Why?
|
| Scattering, Radiation | 2 | 2016 | 316 | 0.240 |
Why?
|
| Submandibular Gland Neoplasms | 2 | 2015 | 37 | 0.240 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 1945 | 0.230 |
Why?
|
| Radiation Oncologists | 1 | 2023 | 29 | 0.230 |
Why?
|
| Radiotherapy, High-Energy | 3 | 2014 | 295 | 0.230 |
Why?
|
| Lymph Nodes | 6 | 2019 | 2967 | 0.230 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2015 | 155 | 0.230 |
Why?
|
| Models, Theoretical | 3 | 2016 | 785 | 0.230 |
Why?
|
| Risk Factors | 14 | 2020 | 17523 | 0.230 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2018 | 833 | 0.230 |
Why?
|
| Medical Oncology | 6 | 2020 | 1423 | 0.230 |
Why?
|
| Neoplasm Grading | 8 | 2019 | 1742 | 0.230 |
Why?
|
| Stents | 2 | 2020 | 1096 | 0.230 |
Why?
|
| Signal-To-Noise Ratio | 2 | 2020 | 117 | 0.220 |
Why?
|
| Neck Dissection | 3 | 2015 | 290 | 0.220 |
Why?
|
| Risk Assessment | 10 | 2021 | 6869 | 0.220 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2020 | 925 | 0.220 |
Why?
|
| Watchful Waiting | 2 | 2015 | 289 | 0.220 |
Why?
|
| Comorbidity | 4 | 2020 | 2352 | 0.220 |
Why?
|
| DNA Damage | 3 | 2021 | 1954 | 0.220 |
Why?
|
| Ependymoma | 2 | 2023 | 242 | 0.220 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 672 | 0.210 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2020 | 1303 | 0.210 |
Why?
|
| Cell Survival | 3 | 2021 | 3045 | 0.210 |
Why?
|
| Tongue Neoplasms | 3 | 2020 | 246 | 0.210 |
Why?
|
| Radiodermatitis | 2 | 2019 | 75 | 0.210 |
Why?
|
| Patient-Centered Care | 2 | 2016 | 294 | 0.210 |
Why?
|
| Risk | 4 | 2017 | 1972 | 0.210 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2023 | 117 | 0.200 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2019 | 67 | 0.200 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2021 | 76 | 0.200 |
Why?
|
| Reproducibility of Results | 7 | 2019 | 6009 | 0.200 |
Why?
|
| Radiobiology | 1 | 2021 | 56 | 0.200 |
Why?
|
| Retinal Diseases | 1 | 2023 | 179 | 0.200 |
Why?
|
| Taste Buds | 1 | 2020 | 7 | 0.200 |
Why?
|
| Ubiquitin-Specific Proteases | 1 | 2021 | 73 | 0.200 |
Why?
|
| Pharyngeal Neoplasms | 2 | 2013 | 133 | 0.190 |
Why?
|
| Health Resources | 2 | 2019 | 168 | 0.190 |
Why?
|
| Necrosis | 2 | 2021 | 580 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 15862 | 0.190 |
Why?
|
| Rad51 Recombinase | 1 | 2021 | 126 | 0.190 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2020 | 19 | 0.190 |
Why?
|
| Lung Neoplasms | 7 | 2022 | 11538 | 0.190 |
Why?
|
| Entropy | 1 | 2020 | 37 | 0.190 |
Why?
|
| Parotid Neoplasms | 3 | 2019 | 148 | 0.190 |
Why?
|
| Clinical Protocols | 2 | 2018 | 467 | 0.190 |
Why?
|
| Caspase 8 | 1 | 2020 | 145 | 0.190 |
Why?
|
| Prostheses and Implants | 3 | 2011 | 295 | 0.190 |
Why?
|
| Carcinoma, Ductal | 1 | 2021 | 145 | 0.180 |
Why?
|
| Operating Rooms | 1 | 2021 | 122 | 0.180 |
Why?
|
| Endpoint Determination | 2 | 2018 | 176 | 0.180 |
Why?
|
| Anatomic Landmarks | 1 | 2020 | 50 | 0.180 |
Why?
|
| Sebaceous Gland Neoplasms | 2 | 2011 | 99 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 5319 | 0.180 |
Why?
|
| Neoadjuvant Therapy | 5 | 2016 | 4975 | 0.180 |
Why?
|
| Antineoplastic Protocols | 1 | 2020 | 33 | 0.180 |
Why?
|
| Wounds, Gunshot | 1 | 2021 | 102 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 5 | 2013 | 2403 | 0.180 |
Why?
|
| ROC Curve | 4 | 2018 | 1183 | 0.180 |
Why?
|
| Cellular Senescence | 2 | 2019 | 382 | 0.180 |
Why?
|
| Ferrosoferric Oxide | 1 | 2020 | 40 | 0.180 |
Why?
|
| Dry Eye Syndromes | 1 | 2023 | 286 | 0.180 |
Why?
|
| Immobilization | 2 | 2019 | 93 | 0.180 |
Why?
|
| Uveal Neoplasms | 1 | 2021 | 176 | 0.180 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2015 | 1833 | 0.180 |
Why?
|
| Thiosemicarbazones | 1 | 2019 | 23 | 0.180 |
Why?
|
| Orbit Evisceration | 2 | 2024 | 46 | 0.180 |
Why?
|
| Ferric Compounds | 1 | 2020 | 73 | 0.180 |
Why?
|
| Time-to-Treatment | 2 | 2019 | 292 | 0.180 |
Why?
|
| Sarcopenia | 1 | 2021 | 110 | 0.170 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2014 | 840 | 0.170 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 430 | 0.170 |
Why?
|
| Adolescent | 15 | 2023 | 31252 | 0.170 |
Why?
|
| Markov Chains | 1 | 2019 | 175 | 0.170 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2021 | 316 | 0.170 |
Why?
|
| Treatment Failure | 3 | 2019 | 1391 | 0.170 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 4971 | 0.170 |
Why?
|
| Deglutition | 1 | 2020 | 171 | 0.170 |
Why?
|
| Regression Analysis | 7 | 2020 | 1546 | 0.170 |
Why?
|
| Mucositis | 2 | 2016 | 148 | 0.170 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 70 | 0.170 |
Why?
|
| Health Facilities | 1 | 2019 | 79 | 0.160 |
Why?
|
| Magnetics | 2 | 2009 | 107 | 0.160 |
Why?
|
| Lymphocytes | 2 | 2020 | 1234 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2018 | 447 | 0.160 |
Why?
|
| Self Efficacy | 1 | 2020 | 298 | 0.160 |
Why?
|
| Radiology, Interventional | 1 | 2019 | 138 | 0.160 |
Why?
|
| Thoracic Neoplasms | 2 | 2018 | 337 | 0.160 |
Why?
|
| Metal Nanoparticles | 1 | 2020 | 164 | 0.160 |
Why?
|
| Endometrial Neoplasms | 2 | 2019 | 1341 | 0.160 |
Why?
|
| Trigeminal Neuralgia | 1 | 2018 | 42 | 0.160 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2018 | 1226 | 0.150 |
Why?
|
| Lymphopenia | 1 | 2020 | 199 | 0.150 |
Why?
|
| Dura Mater | 1 | 2017 | 73 | 0.150 |
Why?
|
| Minocycline | 1 | 2019 | 182 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2018 | 665 | 0.150 |
Why?
|
| Urologic Diseases | 1 | 2017 | 78 | 0.150 |
Why?
|
| Body Composition | 2 | 2021 | 595 | 0.150 |
Why?
|
| Vocal Cords | 1 | 2018 | 90 | 0.150 |
Why?
|
| Health Status Indicators | 2 | 2017 | 224 | 0.150 |
Why?
|
| Patient Positioning | 2 | 2019 | 195 | 0.150 |
Why?
|
| Analysis of Variance | 5 | 2020 | 2307 | 0.150 |
Why?
|
| Pancreas | 1 | 2021 | 718 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2020 | 291 | 0.150 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2017 | 129 | 0.140 |
Why?
|
| Nasal Cavity | 1 | 2017 | 149 | 0.140 |
Why?
|
| Olfactory Bulb | 1 | 2017 | 119 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 502 | 0.140 |
Why?
|
| Cancer Survivors | 2 | 2020 | 650 | 0.140 |
Why?
|
| Peer Review | 1 | 2016 | 80 | 0.140 |
Why?
|
| Prevalence | 2 | 2016 | 3260 | 0.140 |
Why?
|
| Oropharynx | 1 | 2016 | 74 | 0.140 |
Why?
|
| Mitosis | 1 | 2018 | 615 | 0.140 |
Why?
|
| Data Display | 1 | 2016 | 49 | 0.140 |
Why?
|
| X-Rays | 1 | 2016 | 146 | 0.140 |
Why?
|
| Pharyngeal Muscles | 1 | 2016 | 36 | 0.140 |
Why?
|
| Neutrophils | 1 | 2020 | 835 | 0.140 |
Why?
|
| Peer Review, Health Care | 1 | 2016 | 30 | 0.140 |
Why?
|
| Quality Indicators, Health Care | 2 | 2021 | 348 | 0.140 |
Why?
|
| Causality | 1 | 2016 | 178 | 0.140 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2016 | 82 | 0.130 |
Why?
|
| Mandible | 1 | 2017 | 188 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 1225 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2021 | 1756 | 0.130 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2016 | 167 | 0.130 |
Why?
|
| Cell Cycle Proteins | 2 | 2021 | 2045 | 0.130 |
Why?
|
| RNA-Binding Proteins | 1 | 2021 | 984 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2019 | 627 | 0.130 |
Why?
|
| Radiation Exposure | 1 | 2016 | 73 | 0.130 |
Why?
|
| Ultrasonography | 2 | 2019 | 1863 | 0.130 |
Why?
|
| Myoepithelioma | 1 | 2015 | 31 | 0.130 |
Why?
|
| Tadalafil | 1 | 2014 | 4 | 0.130 |
Why?
|
| Attitude of Health Personnel | 2 | 2020 | 918 | 0.130 |
Why?
|
| Physical Examination | 1 | 2016 | 299 | 0.130 |
Why?
|
| Radiopharmaceuticals | 5 | 2013 | 1301 | 0.130 |
Why?
|
| Curriculum | 1 | 2020 | 860 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2020 | 6207 | 0.130 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 4892 | 0.130 |
Why?
|
| Morbidity | 1 | 2016 | 397 | 0.130 |
Why?
|
| Hypothyroidism | 1 | 2016 | 204 | 0.120 |
Why?
|
| Reference Values | 1 | 2016 | 1099 | 0.120 |
Why?
|
| Gastrostomy | 1 | 2016 | 180 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2023 | 3719 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2017 | 295 | 0.120 |
Why?
|
| Proportional Hazards Models | 6 | 2023 | 4988 | 0.120 |
Why?
|
| Seminoma | 1 | 2014 | 81 | 0.120 |
Why?
|
| Learning Curve | 1 | 2014 | 68 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 598 | 0.120 |
Why?
|
| Pyruvic Acid | 1 | 2015 | 133 | 0.120 |
Why?
|
| Fatigue | 3 | 2019 | 1239 | 0.120 |
Why?
|
| Enteral Nutrition | 1 | 2016 | 316 | 0.120 |
Why?
|
| Carotid Arteries | 2 | 2019 | 240 | 0.120 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2018 | 607 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 860 | 0.120 |
Why?
|
| Nasolacrimal Duct | 1 | 2013 | 53 | 0.120 |
Why?
|
| Fear | 1 | 2015 | 254 | 0.120 |
Why?
|
| Antineoplastic Agents | 6 | 2019 | 14289 | 0.110 |
Why?
|
| Sublingual Gland Neoplasms | 1 | 2012 | 3 | 0.110 |
Why?
|
| Delphi Technique | 3 | 2023 | 210 | 0.110 |
Why?
|
| Muscle, Skeletal | 2 | 2021 | 1270 | 0.110 |
Why?
|
| Genital Neoplasms, Female | 1 | 2019 | 735 | 0.110 |
Why?
|
| Evidence-Based Medicine | 3 | 2015 | 1085 | 0.110 |
Why?
|
| Temperature | 1 | 2014 | 506 | 0.110 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2015 | 624 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 333 | 0.110 |
Why?
|
| Chordoma | 1 | 2014 | 163 | 0.110 |
Why?
|
| Coitus | 1 | 2012 | 25 | 0.110 |
Why?
|
| Proteomics | 1 | 2019 | 1380 | 0.110 |
Why?
|
| Vomiting | 1 | 2014 | 354 | 0.110 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 4298 | 0.110 |
Why?
|
| Age Factors | 6 | 2020 | 5377 | 0.100 |
Why?
|
| Nausea | 1 | 2014 | 525 | 0.100 |
Why?
|
| Cystectomy | 1 | 2016 | 623 | 0.100 |
Why?
|
| Chondrosarcoma | 1 | 2014 | 216 | 0.100 |
Why?
|
| Postoperative Period | 1 | 2013 | 665 | 0.100 |
Why?
|
| Biomarkers | 3 | 2022 | 5047 | 0.100 |
Why?
|
| Synchrotrons | 2 | 2022 | 35 | 0.100 |
Why?
|
| International Agencies | 1 | 2011 | 107 | 0.100 |
Why?
|
| Ultrasonography, Interventional | 1 | 2014 | 429 | 0.100 |
Why?
|
| Software | 2 | 2015 | 1321 | 0.100 |
Why?
|
| Incidence | 4 | 2020 | 5673 | 0.100 |
Why?
|
| Forecasting | 1 | 2014 | 694 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2016 | 621 | 0.100 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2015 | 489 | 0.100 |
Why?
|
| Image Enhancement | 2 | 2016 | 561 | 0.100 |
Why?
|
| Tissue Distribution | 1 | 2012 | 875 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2015 | 2803 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2019 | 11965 | 0.100 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 2864 | 0.100 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2011 | 65 | 0.090 |
Why?
|
| Cornea | 1 | 2015 | 638 | 0.090 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2012 | 342 | 0.090 |
Why?
|
| Medicare | 3 | 2020 | 860 | 0.090 |
Why?
|
| Glucose | 1 | 2016 | 1248 | 0.090 |
Why?
|
| Anisotropy | 1 | 2010 | 181 | 0.090 |
Why?
|
| Foreign-Body Migration | 1 | 2011 | 117 | 0.090 |
Why?
|
| Urinary Retention | 1 | 2009 | 21 | 0.090 |
Why?
|
| Child | 5 | 2023 | 29154 | 0.090 |
Why?
|
| Mesothelioma | 1 | 2015 | 544 | 0.090 |
Why?
|
| Anxiety Disorders | 1 | 2015 | 666 | 0.090 |
Why?
|
| Feasibility Studies | 3 | 2023 | 2292 | 0.080 |
Why?
|
| Consensus | 3 | 2021 | 978 | 0.080 |
Why?
|
| SEER Program | 3 | 2019 | 1000 | 0.080 |
Why?
|
| Mass Screening | 2 | 2017 | 1509 | 0.080 |
Why?
|
| Device Removal | 1 | 2011 | 337 | 0.080 |
Why?
|
| Glass | 1 | 2008 | 30 | 0.080 |
Why?
|
| Nitrates | 1 | 2008 | 43 | 0.080 |
Why?
|
| Acrylates | 1 | 2008 | 30 | 0.080 |
Why?
|
| Biopsy | 2 | 2014 | 3443 | 0.080 |
Why?
|
| Cervical Vertebrae | 2 | 2020 | 205 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 3472 | 0.080 |
Why?
|
| Skin Neoplasms | 2 | 2015 | 4654 | 0.080 |
Why?
|
| Palliative Care | 2 | 2018 | 2037 | 0.080 |
Why?
|
| Registries | 1 | 2016 | 2170 | 0.080 |
Why?
|
| Cross-Sectional Studies | 4 | 2019 | 4314 | 0.080 |
Why?
|
| Cause of Death | 3 | 2020 | 752 | 0.080 |
Why?
|
| Career Choice | 2 | 2006 | 232 | 0.080 |
Why?
|
| Acute Disease | 2 | 2009 | 2422 | 0.080 |
Why?
|
| Radiology | 1 | 2013 | 434 | 0.070 |
Why?
|
| Conjunctival Neoplasms | 1 | 2008 | 120 | 0.070 |
Why?
|
| Disease Progression | 5 | 2018 | 6682 | 0.070 |
Why?
|
| Self Report | 3 | 2017 | 756 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 3552 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 383 | 0.070 |
Why?
|
| Benchmarking | 2 | 2021 | 273 | 0.070 |
Why?
|
| Dogs | 1 | 2008 | 1155 | 0.070 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2009 | 340 | 0.070 |
Why?
|
| Organ Specificity | 1 | 2008 | 699 | 0.070 |
Why?
|
| Logistic Models | 3 | 2020 | 3441 | 0.070 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 15694 | 0.070 |
Why?
|
| Health Surveys | 1 | 2007 | 402 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 4757 | 0.070 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 4320 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 5112 | 0.070 |
Why?
|
| Larynx | 2 | 2017 | 134 | 0.070 |
Why?
|
| Laryngectomy | 2 | 2017 | 242 | 0.070 |
Why?
|
| Linear Models | 1 | 2008 | 1085 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 1162 | 0.060 |
Why?
|
| Bayes Theorem | 2 | 2020 | 1021 | 0.060 |
Why?
|
| Cell Cycle | 2 | 2021 | 2084 | 0.060 |
Why?
|
| Educational Measurement | 1 | 2006 | 362 | 0.060 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2004 | 88 | 0.060 |
Why?
|
| Rats | 1 | 2012 | 6086 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 10331 | 0.060 |
Why?
|
| Kidney | 1 | 2012 | 2146 | 0.060 |
Why?
|
| Remission Induction | 1 | 2010 | 3569 | 0.060 |
Why?
|
| Patient Outcome Assessment | 2 | 2015 | 245 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 2341 | 0.060 |
Why?
|
| Tonsillectomy | 2 | 2016 | 102 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2016 | 3890 | 0.050 |
Why?
|
| Liver | 1 | 2012 | 2961 | 0.050 |
Why?
|
| Sleep Wake Disorders | 2 | 2019 | 348 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 1363 | 0.050 |
Why?
|
| Motion | 2 | 2015 | 193 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2016 | 980 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2004 | 297 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 3821 | 0.050 |
Why?
|
| Human papillomavirus 16 | 2 | 2016 | 256 | 0.050 |
Why?
|
| Salivary Ducts | 1 | 2021 | 56 | 0.050 |
Why?
|
| Deubiquitinating Enzymes | 1 | 2021 | 38 | 0.050 |
Why?
|
| Animals | 4 | 2021 | 59536 | 0.050 |
Why?
|
| Brain | 3 | 2021 | 4113 | 0.050 |
Why?
|
| Professional Practice Location | 1 | 2020 | 16 | 0.050 |
Why?
|
| Hep G2 Cells | 1 | 2021 | 155 | 0.050 |
Why?
|
| Geography, Medical | 1 | 2020 | 21 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2021 | 2203 | 0.050 |
Why?
|
| Urban Health Services | 1 | 2020 | 37 | 0.050 |
Why?
|
| Biomimetics | 1 | 2020 | 33 | 0.050 |
Why?
|
| Caspase Inhibitors | 1 | 2020 | 95 | 0.050 |
Why?
|
| Rural Health Services | 1 | 2020 | 39 | 0.050 |
Why?
|
| Electric Impedance | 1 | 2021 | 100 | 0.050 |
Why?
|
| Linear Energy Transfer | 1 | 2021 | 98 | 0.050 |
Why?
|
| HCT116 Cells | 1 | 2021 | 348 | 0.050 |
Why?
|
| Tongue | 1 | 2020 | 77 | 0.050 |
Why?
|
| Smoking | 3 | 2016 | 2440 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2020 | 130 | 0.050 |
Why?
|
| Dipeptides | 1 | 2020 | 91 | 0.050 |
Why?
|
| Homologous Recombination | 1 | 2021 | 185 | 0.050 |
Why?
|
| Quality Improvement | 2 | 2019 | 851 | 0.050 |
Why?
|
| Mouth Mucosa | 1 | 2020 | 216 | 0.050 |
Why?
|
| Proteogenomics | 1 | 2020 | 87 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2022 | 341 | 0.050 |
Why?
|
| Dental Impression Technique | 1 | 2019 | 17 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2021 | 149 | 0.040 |
Why?
|
| Temporal Lobe | 1 | 2021 | 192 | 0.040 |
Why?
|
| Smokers | 1 | 2020 | 143 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2021 | 550 | 0.040 |
Why?
|
| Peripheral Nerves | 1 | 2020 | 159 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2019 | 246 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2023 | 938 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2019 | 6100 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 684 | 0.040 |
Why?
|
| Physicians, Women | 1 | 2020 | 105 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 486 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2021 | 314 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2019 | 45 | 0.040 |
Why?
|
| Equipment and Supplies | 1 | 2019 | 48 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2020 | 217 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 388 | 0.040 |
Why?
|
| Kallikreins | 1 | 2019 | 84 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2018 | 2218 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2023 | 1944 | 0.040 |
Why?
|
| Head | 1 | 2020 | 249 | 0.040 |
Why?
|
| Breakthrough Pain | 1 | 2018 | 17 | 0.040 |
Why?
|
| Mitochondrial Proteins | 1 | 2020 | 369 | 0.040 |
Why?
|
| Survivors | 2 | 2015 | 1031 | 0.040 |
Why?
|
| Intestine, Large | 1 | 2018 | 28 | 0.040 |
Why?
|
| Quality Control | 1 | 2019 | 457 | 0.040 |
Why?
|
| Pharynx | 1 | 2019 | 153 | 0.040 |
Why?
|
| Neck Pain | 1 | 2018 | 39 | 0.040 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2017 | 15 | 0.040 |
Why?
|
| Caspases | 1 | 2020 | 661 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 5159 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2021 | 597 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2018 | 158 | 0.040 |
Why?
|
| Gallium Radioisotopes | 1 | 2017 | 60 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 1313 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 621 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2021 | 1643 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 452 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2020 | 745 | 0.040 |
Why?
|
| Time | 1 | 2017 | 178 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 7222 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 2017 | 295 | 0.040 |
Why?
|
| Survivorship | 1 | 2017 | 109 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2018 | 285 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2021 | 1489 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 1533 | 0.040 |
Why?
|
| Teaching Rounds | 1 | 2016 | 33 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2016 | 418 | 0.030 |
Why?
|
| Steroids | 1 | 2018 | 356 | 0.030 |
Why?
|
| Palate, Soft | 1 | 2016 | 28 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 854 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2019 | 492 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 700 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 497 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 1 | 2016 | 310 | 0.030 |
Why?
|
| Urogenital Neoplasms | 1 | 2016 | 108 | 0.030 |
Why?
|
| DNA Replication | 1 | 2019 | 744 | 0.030 |
Why?
|
| Medical Audit | 1 | 2016 | 188 | 0.030 |
Why?
|
| Etoposide | 1 | 2017 | 870 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2021 | 1274 | 0.030 |
Why?
|
| Indoles | 1 | 2020 | 1009 | 0.030 |
Why?
|
| Biological Transport | 1 | 2016 | 597 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2017 | 436 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2015 | 102 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2020 | 2316 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 1265 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 1439 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 1271 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2016 | 556 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2020 | 2450 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 625 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2018 | 953 | 0.030 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2014 | 84 | 0.030 |
Why?
|
| Length of Stay | 1 | 2021 | 1900 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 107 | 0.030 |
Why?
|
| Cetuximab | 1 | 2015 | 472 | 0.030 |
Why?
|
| Histones | 1 | 2021 | 1466 | 0.030 |
Why?
|
| Sexuality | 1 | 2013 | 38 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2015 | 756 | 0.030 |
Why?
|
| Tosyl Compounds | 1 | 2013 | 40 | 0.030 |
Why?
|
| Mitochondria | 1 | 2020 | 1282 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 1148 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2015 | 250 | 0.030 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2014 | 142 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2015 | 267 | 0.030 |
Why?
|
| Radiation Monitoring | 1 | 2013 | 49 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 739 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2021 | 4804 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 4938 | 0.030 |
Why?
|
| Orchiectomy | 1 | 2013 | 214 | 0.030 |
Why?
|
| Medicaid | 1 | 2015 | 279 | 0.030 |
Why?
|
| Carboplatin | 1 | 2015 | 823 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2021 | 5542 | 0.030 |
Why?
|
| Protein Binding | 1 | 2019 | 3438 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 5637 | 0.030 |
Why?
|
| Kinetics | 1 | 2015 | 2049 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2021 | 1471 | 0.030 |
Why?
|
| Neck | 1 | 2015 | 383 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 2083 | 0.030 |
Why?
|
| Sickness Impact Profile | 1 | 2012 | 139 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 915 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 1290 | 0.030 |
Why?
|
| Weight Loss | 1 | 2016 | 627 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2021 | 2518 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2016 | 451 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 592 | 0.030 |
Why?
|
| Brain Stem | 1 | 2012 | 175 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2016 | 502 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2013 | 211 | 0.020 |
Why?
|
| Melanoma | 1 | 2008 | 5317 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 966 | 0.020 |
Why?
|
| Anilides | 1 | 2013 | 268 | 0.020 |
Why?
|
| Cognition | 1 | 2017 | 968 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 324 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2019 | 3154 | 0.020 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2011 | 115 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 1258 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2013 | 441 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 360 | 0.020 |
Why?
|
| Carbon | 1 | 2011 | 149 | 0.020 |
Why?
|
| Models, Biological | 1 | 2019 | 3254 | 0.020 |
Why?
|
| Pain | 1 | 2019 | 1658 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 1350 | 0.020 |
Why?
|
| Quinazolines | 1 | 2015 | 923 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2330 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 1053 | 0.020 |
Why?
|
| Gold | 1 | 2011 | 270 | 0.020 |
Why?
|
| Rhabdomyosarcoma | 1 | 2013 | 341 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2011 | 660 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2014 | 598 | 0.020 |
Why?
|
| Mice | 2 | 2021 | 34495 | 0.020 |
Why?
|
| Intestines | 1 | 2013 | 686 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2012 | 690 | 0.020 |
Why?
|
| Nitriles | 1 | 2013 | 906 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 1371 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2016 | 929 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 4821 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2012 | 764 | 0.020 |
Why?
|
| Efficiency | 1 | 2007 | 99 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2019 | 7226 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2007 | 233 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2011 | 636 | 0.020 |
Why?
|
| Disease Management | 1 | 2011 | 1052 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2012 | 1000 | 0.020 |
Why?
|
| Private Practice | 1 | 2005 | 31 | 0.020 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2005 | 84 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 1959 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 495 | 0.010 |
Why?
|
| Amifostine | 1 | 2004 | 97 | 0.010 |
Why?
|
| Lung | 1 | 2015 | 3151 | 0.010 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2011 | 1415 | 0.010 |
Why?
|
| Radiation-Protective Agents | 1 | 2004 | 128 | 0.010 |
Why?
|
| Glioma | 1 | 2014 | 1963 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 1323 | 0.010 |
Why?
|
| Mutation | 1 | 2020 | 15179 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2007 | 1171 | 0.010 |
Why?
|
| Sex Factors | 1 | 2005 | 2139 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 4849 | 0.010 |
Why?
|